Cerulean Pharma Inc. (CERU) announced Monday morning that it has entered into a definitive stock purchase agreement with privately-held Daré Bioscience through which equityholders of Daré Bioscience will become the majority owners of Cerulean.
Cerulean Pharma has gapped open sharply lower this morning and is now down 2.09 at $1.23 on above average volume. The stock has dropped to a 3-week low.
For comments and feedback contact: editorial@rttnews.com
Business News
May 15, 2026 15:25 ET Apart from the confirmation of Kevin Warsh as the next Fed chair, the main news on the economics front this week included key price data from the U.S. and the first quarter economic growth figures from major economies. Both consumer prices and producer costs have started to reflect the effect of supply shocks due to the Middle East conflict. In Europe, GDP data was in focus, while inflation data from China dominated the news flow in Asia.